Results 181 to 190 of about 144,495 (335)
AutoSAS: A new human-aside-the-loop paradigm for automated SAS fitting for high throughput and autonomous experimentation. [PDF]
Sutherland DR+4 more
europepmc +1 more source
Rewiring Neuroimmunity: Nanoplatform Innovations for CNS Disease Therapy
This review explores emerging nanoplatform strategies designed to modulate neuroimmune responses for treating central nervous system (CNS) disorders. It examines structural and microenvironmental barriers, advances in multifunctional and targeted nanotechnologies, and highlights clinical progress and translational challenges, offering insights into the
Muhammad Usman Akbar+7 more
wiley +1 more source
Formation of a Micelle-like Structure in Aqueous Solution of 1, 4-Hexanediol.
Yuriko Kato
openalex +2 more sources
WSGC peptide reverses drug resistance in GA by modulating the Notch signaling pathway and mitophagy at the molecular level. Abstract This study investigates the molecular mechanisms by which superparamagnetic iron oxide nanoparticles (SPIONs) loaded with the WSGC peptide (WSGC@FA@PEG/PEI‐SPIONs)—a 40‐amino acid polypeptide derived from apoC‐III ...
Dongjian Song+10 more
wiley +1 more source
Detergent Choice Shapes the Solution Structures of Photosystems I and II: Implications for Crystallization and High-Resolution Studies. [PDF]
Golub M+8 more
europepmc +1 more source
The change in acid strength of acidic dye molecule and organic ligand on the micelle surface.
Hitoshi KOHARA
openalex +2 more sources
SIRT3 expression is significantly downregulated in the aged kidney, rendering the kidney more vulnerable to fibrotic changes in obstructive nephropathy. By promoting GSK‐3β deacetylation, SIRT3 indirectly inhibits Wnt/β‐catenin signaling, thereby suppressing renal fibrosis.
Jing Wang+11 more
wiley +1 more source
Semicontinuous Microemulsion Polymerization of Polymeric Nanoparticles of Poly(cyanoacrylates) and Poly(caprolactone). [PDF]
León-Sánchez G+6 more
europepmc +1 more source
Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration
There are multiple therapeutic agents available for the treatment of both dry age‐related macular degeneration (AMD) and wet AMD. It is essential to continue innovation by introducing new drug delivery technologies that can incorporate those along with patient compliance and the accessibility of the technology into the early stages of research and ...
J Jesus Rodriguez‐Cruz+4 more
wiley +1 more source